Gastric Ulcers - Pipeline Insight, 2024

This Gastric Ulcers - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gastric Ulcers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gastric Ulcers Understanding

Gastric Ulcers: Overview

Gastric ulcers are a break in the mucosa of the stomach lining that penetrates through the muscularis mucosa and extends more than 5 mm in diameter. When alterations occur to the defense mechanisms of the stomach, it can cause changes in the gastric mucosa which will eventually result in erosion and then ulceration. This activity reviews the evaluation and management of gastric ulcers and explains the role of the interprofessional team in improving care for patients with this condition.

The most common etiologies of gastric ulcers include a bacterial infection with Helicobacter pylori and gastric prostaglandin loss associated with non-steroidal anti-inflammatory medications. Less common etiologies include hypergastrinemia (Zollinger-Ellison syndrome), viral infections such as CMV, chemotherapy and radiation, gastric outlet obstruction, gastric infiltrative disorders such as malignancy, cigarette smoking, and Crohn disease. The common factor in all of these etiologies is that they promote a breakdown in the mucosal barrier and expose the gastric mucosa to the damaging effects of acid.

The pathophysiology of gastric ulcer development depends on the insult. Since about 80 to 90% of gastric ulcers result from either Helicobacter pylori and/or NSAID use.

Gastric Ulcers - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Ulcers pipeline landscape is provided which includes the disease overview and Gastric Ulcers treatment guidelines. The assessment part of the report embraces, in depth Gastric Ulcers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Ulcers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Gastric Ulcers. The therapies under development are focused on novel approaches to treat/improve Gastric Ulcers.

This segment of the Gastric Ulcers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastric Ulcers Emerging Drugs

Tegoprazan: RaQualia PharmaTegoprazan is a gastric acid secretion inhibitor with a new mechanism called potassium-competitive acid blocker (P-CAB) that was created by RaQualia Pharma. P-CAB has a different mechanism from proton pump inhibitors (PPI), which are the first drug of choice for the treatment of gastroesophageal reflux disease (GERD).

Gastric Ulcers: Therapeutic Assessment

This segment of the report provides insights about the Gastric Ulcers drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gastric Ulcers

There are approx. 5+ key companies which are developing the therapies Gastric Ulcers. The companies which have their Gastric Ulcers drug candidates in the most advanced stage, i.e Phase III include, RaQualia Pharma.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Gastric Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastric Ulcers: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Ulcers therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Ulcers drugs.

Gastric Ulcers Report Insights

• Gastric Ulcers Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gastric Ulcers Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gastric Ulcers drugs?
• How many Gastric Ulcers drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Ulcers?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastric Ulcers therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastric Ulcers and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• RaQualia Pharma
• KindredBio
• Daewoong Pharmaceutical Co
• Pharmaking Ltd.
• Sam-A Pharm Co. Ltd.
• Xuanzhu Pharma Co

Key Products

• Tegoprazan
• KIND-014
• Lansoprazole
• PMK S005

This product will be delivered within 2 business days.